Crispr Therapeutics AG 8-K filings

CRISPR Therapeutics announced robust second quarter 2026 financial results, highlighted by significant revenue growth for CASGEVY and progress across its diverse pipeline of gene-editing therapies.

CRISPR Therapeutics shareholders approved the 2026 Stock Option and Incentive Plan and amended the company's articles of association at the 2026 Annual General Meeting.

CRISPR Therapeutics announced its first quarter 2026 financial results, highlighting $43 million in CASGEVY revenue and progress across its diverse pipeline of gene-editing therapies.

CRISPR Therapeutics AG successfully closed its private offering of $600 million in 1.7308% Convertible Senior Notes due 2031, bolstering its financial position for general corporate purposes.

CRISPR Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting continued progress across its diverse gene-editing pipeline and global uptake of CASGEVY.

CRISPR Therapeutics AG announced significant progress across its cardiovascular, autoimmune, immuno-oncology, and regenerative medicine programs, including positive clinical data and new collaborations.

CRISPR Therapeutics announced its third quarter 2025 financial results, highlighting accelerating CASGEVY commercialization, positive CTX310 Phase 1 data, and advancements across its gene-editing pipeline.

CRISPR Therapeutics AG announced a prospectus supplement to offer and sell up to $600 million in common shares through an at-the-market offering.

CRISPR Therapeutics reported its second quarter 2025 financial results, highlighting significant progress in its gene-editing pipeline and the commercial rollout of CASGEVY, despite an increased net loss.

CRISPR Therapeutics AG announced new positive data for its CTX310 cardiovascular program, showing significant reductions in cholesterol and triglycerides, while simultaneously delaying the next update for its CTX320 program to the first half of 2026.

CRISPR Therapeutics AG shareholders approved all management proposals at its 2025 Annual General Meeting, including amendments to its Articles of Association, re-election of board members, and executive compensation plans, despite notable dissent on certain compensation-related items.

CRISPR Therapeutics AG will collaborate with Sirius Therapeutics to develop siRNA technology targeting Factor XI, issuing $70 million in common shares and $25 million in cash upfront.

CRISPR Therapeutics reports promising initial data from its CTX310 Phase 1 trial, showing significant reductions in triglycerides and LDL, alongside its Q1 2025 financial results.

Julianne Bruno, Chief Operating Officer of CRISPR Therapeutics, will step down on April 11, 2025, to pursue external opportunities.

CRISPR Therapeutics announces its Q4 and full-year 2024 financial results, highlighting progress with CASGEVY launch and advancements in its clinical pipeline.

CRISPR Therapeutics reported its third quarter 2024 financial results, highlighted by regulatory approvals for CASGEVY in Switzerland and Canada and advancements across its gene-editing pipeline.

CRISPR Therapeutics announced its Q2 2024 financial results and provided updates on its clinical programs, including the launch of CASGEVY and progress in CAR T and in vivo gene editing therapies.

CRISPR Therapeutics' shareholders approved an increase in shares reserved for issuance under the 2018 Stock Option and Incentive Plan and amendments to the company's articles of association at their annual general meeting.

CRISPR Therapeutics AG has promoted Julianne Bruno to Chief Operating Officer, effective May 23, 2024.

CRISPR Therapeutics announced its first quarter 2024 financial results and provided updates on its clinical programs, including the expansion of its in vivo gene editing pipeline.

CRISPR Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting the approval of CASGEVY and progress across its gene-editing pipeline.

CRISPR Therapeutics has entered into an investment agreement to issue approximately 3.9 million common shares at $71.50 per share, raising about $280 million before expenses.

CRISPR Therapeutics and Vertex Pharmaceuticals' jointly developed gene therapy, CASGEVY, has been granted conditional marketing authorization by the European Commission for treating severe sickle cell disease and transfusion-dependent beta thalassemia.

The U.S. Food and Drug Administration has approved CRISPR Therapeutics' CASGEVY gene therapy for treating transfusion-dependent beta thalassemia in patients 12 years and older.